About the Lab

Recent Reviews

Recent Synthetic Approaches to anticancer 9-anilinoacridines

http://www.tandfonline.com/doi/abs/10.1080/00304948.2012.676510?journalCode=uopp20

Targeted drug delivery for cancer therapy: the other side of antibodies

http://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-5-70

Recent Developments in the Synthesis and Applications of Anticancer Amonafide Derivatives.

http://benthamscience.com/journals/letters-in-drug-design-and discovery/volume/13/issue/1/page/47/

”Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells”,
Gilad Y., Firer M., Gellerman G., Biomedicines 2016, 4, 11; 1-24.

http://www.mdpi.com/2227-9059/4/2/11

 

About the LAB

In the Gellerman’s Group, we specialise in developing new conjugation methods of drug ‘cocktails’ to peptide carriers and applying them to the targeted drug delivery (TDD.

The conjugation of drugs is carried out through novel multifunctional platforms with programmed release capabilities. These platforms can carry different anticancer “cocktails” and are designed to release linked drugs in a time-dependent mode. By conjugation to the specific carrier, these platforms almost exclusively enter the cancer cells rather than healthy tissue, ensuring much less toxic treatment. Over the last 5 years we have worked on several projects associated with metastatic solid tumour malignancies and came out with leads that are currently evaluated in animal models. In addition to our research on peptide based TDD, we develop bifunctional, binuclear and chimeric anticancer molecules with improved bioactivity and ready to use in TDD. We also specialize in state-of-the-art solid phase chemistry (SPOC), organic heterocyclic chemistry and synthesis of fluorescent biomarkers. Group members and our publication list please see at the group website